Layers upon layers. Too many silos. CE, NPS, and now this hybrid of MPA role. All have their own managers, RDs, and EDs. Novartis needs to cutback the leadership levels. Too many chiefs, not enough Indians. With 2025 expected performance being way below expectations, this is where the cuts need to happen.